ATM protein synthesis patterns in sporadic breast cancer

Journal of Clinical Pathology - Molecular Pathology

Volumn 52, Issue 5, 1999, Pages 252-256

  Kairouz, R ^a   Clarke, R A ^a   Marr, P J ^a   Watters, D ^b   Lavin, M F ^b   Kearsley, J H ^a   Soon Lee, C ^c  

^a ST GEORGE HOSPITAL   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

ATM gene; Breast carcinoma; Metastases; Tumour suppressor

Indexed keywords

ARTICLE; ATAXIA TELANGIECTASIA; BREAST CANCER; CANCER RISK; CARCINOMA IN SITU; GENE MUTATION; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS;

EID: 0032887367     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.52.5.252     Document Type: Article

References (29)

1. Easton DF. Cancer risk in A-T heterozygotes. Int J Radiat Biol 1994;66:177-82.
2. Gatti RA, Berkel I, Boder E, et al. Localisation of the ataxia-telangiectasia gene to chromosome 11q22 23. Nature 1988;336:577-80.
3. Lavin MF, Shiloh Y. The genetic defect in ataxia-telangiectasia. Annu Rev Immunol 1997;15:177-202.
4. Swift M, Reitnauer PJ, Morrell D, et al. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987;316:1289-94.
5. Swift M, Morrell D, Massey RB, et al. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991;325:1831-6.
6. Athma P, Rappaport R, Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 1996;92:130-4.
7. Bishop DT, Hopper J. A-T-tributable risks? Nat Genet 1997; 15:226.
8. Fitzgerald MG, Bean JM, Hedge SR, et al. Heterozygous ATM mutations do not contribute to early onset breast cancer. Nat Genet 1997;5:307-10.
9. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia-telangiectasia gene with a product similar to PI-3 kinase. Science 1995;268:1749-53.
10. Kastan MB, Zhan O, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587-97.
11. Khanna KK, Beamish H, Yan J, et al. Nature of GI/S cell cycle checkpoint defect in ataxia-telangiectasia. Oncogene 1995;11:609-18.
12. Savitsky K, Sfez S, Tagle DA, et al. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet 1995;4:2025-32.
13. Canman CE, Wolff AC, Chen CY, et al. The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res 1994;54:5054-8.
14. Byrd PJ, McConville CM, Cooper P, et al. Mutations revealed by sequencing the 5′ half of the gene for ataxia-telangiectasia. Hum Mol Genet 1996;5:145-9.
15. Telatar M, Wang Z, Udar W, et al. Ataxia telangiectasia: mutations in cDNA detected by protein truncation screening. Am J Hum Genet 1996;59:40-4.
16. Gilad S, Khosravi R, Shkedy D, et al. Predominance of null mutations in ataxia-telangiectasia. Hum Mol Genet 1996;5:433-40.
17. Man S, Ellis IO, Sibbering M, et al. High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. Cancer Res 1996;56:5484-9.
18. Vorechovsky I, Rasio D, Luo L, et al. The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumours reveals no evidence for mutation. Cancer Res 1996;56:2726-32.
19. Watters D, Khanna KK, Beamish H, et al. Cellular localisation of the ataxia telangiectasia (ATM) gene product and discrimination between mutated and normal forms. Oncogene 1997;14:1911-21.
20. Boenisch T. Staining methods. In: Naisch SJ, ed. Handbook of immunochemical staining methods. California: DAKO Corporation, 1989:16-18.
21. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long term follow-up. Histopathology 1992;19:403-10.
22. Roest PAM, Roberts RG, Sugino S, et al. Protein truncation test (PTT) for rapid detection of translation-terminating mutations. Hum Mol Genet 1993;2:1719-21.
23. Clarke RA, Goozee G, Birrell G, et al. Absence of ATM truncation mutations in patients with severe acute radiation reactions. Int J Radiat Oncol Biol Phys 1998;41:1021-7.
24. Vorechovsky I, Luo L, Dyer MJS, et al. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat Genet 1997;17:96-9.
25. Clarke RA, Kairouz R, Watters D, et al. Up-regulation of ATM in sclerosing adenosis in the breast. J Clin Pathol: Mol Pathol 1998;51:224-6.
26. Tomlinson IPM, Stickland JE, Lee ASG, et al. Loss of heterozygosity on chromosome 11q in breast cancer. J Clin Pathol 1995;48:424-8.
27. Sakai T, Toguchida J, Ohtani N, et al. Allele-specific hypermethylation of the retinoblastoma tumor-supressor gene. Am J Hum Genet 1991;48:880-8.
28. Gonzalez-Zulueta M, Bender CM, Yang AS, et al. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995;55:4531-5.
29. Borreson AL, Andersen TI, Treti S, et al. Breast cancer and other cancers in Norwegian families with ataxia-telangiectasia. Genes Chromosomes Cancer 1990;2:339-40.